Scindeks Asistent Scindeks Asistent — Sistem za uređivanje časopisa
Vol. 78 Br. 3 (2021)
Vol. 78 Br. 3 (2021)

Dugoročno praćenje odgovora posredovanog antitelima posle primarne ekspozicije SARS-COV-2 i posle mRNA COVID-19 vakcinacije: Prikaz slučaja

DOI: 10.2298/VSP200220019B
Bela Balint
Serbian Academy of Sciences and Arts, Department of Medical Sciences, Belgrade, Serbia
Milena Todorović Balint
University Clinical Center of Serbia, Clinic for Hematology, Belgrade, Serbia
Zorana Andrić
Blood Transfusion Institute of Serbia, Belgrade, Serbia
Milica Jovičić
Blood Transfusion Institute of Serbia, Belgrade, Serbia
Glorija Blagojević
Blood Transfusion Institute of Serbia, Belgrade, Serbia
Miodrag Čolić
Serbian Academy of Sciences and Arts, Department of Medical Sciences, Belgrade, Serbia
PDF (engleski)

Objavljeno

2021-04-02

Sekcija

Pismo Uredniku

Kako citirati

1.
Balint B, Todorović Balint M, Andrić Z, Jovičić M, Blagojević G, Čolić M. Dugoročno praćenje odgovora posredovanog antitelima posle primarne ekspozicije SARS-COV-2 i posle mRNA COVID-19 vakcinacije: Prikaz slučaja. Vojnosanit Pregl [Internet]. 02. April 2021. [citirano 12. Juli 2026.];78(3). Dostupno na: https://asistent.ceon.rs/index.php/vsp/article/view/30957
ACS APA ABNT Chicago Harvard IEEE Vancouver

Preuzimanje za menagere referenci

Endnote/Zotero/Mendeley (RIS) BibTeX

Ključne reči

antitela
covid-19
covid-19 seroterapija
infekcije
vakcinacija
DOI: 10.2298/VSP200220019B

Reference

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Throm-bosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383(2): 120–8.

Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife 2020; 9: e59177.

Khalaf K, Papp N, Chou JT, Hana D, Mackiewicz A, Kaczmarek M. SARS-CoV-2: Pathogenesis, and advancements in diagnos-tics and treatment. Front Immunol 2020; 11: 570927.

Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, et al. Treatment options for COVID-19: A review. Front Med (Lausanne) 2020; 7: 480.

Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, et al. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs 2020; 12(1): 1854149.

Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020; 370(6521): 1227–30.

Yin S, Tong X, Huang A, Shen H, Li Y, Liu Y, et al. Longitudi-nal anti-SARS-CoV-2 antibody profile and neutralization ac-tivity of a COVID-19 patient. J Infect 2020; 81(3): e31–e32.

Xu TM, Lin B, Chen C, Liu LG, Xue Y. Non-optimal effec-tiveness of convalescent plasma transfusion and hydroxychlo-roquine in treating COVID-19: a case report. Virol J 2020; 17(1): 80.

Zeng H, Wang D, Nie J, Liang H, Gu J, Zhao A, et al. The effi-cacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. Signal Transduct Target Ther 2020; 5(1): 219.

Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol 2021; 222: 108634.

Awadasseid A, Wu Y, Tanaka Y, Zhang W. Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci 2021; 17(1): 8–19.

Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371(6529): eabf4063.